Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact on +44 or for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Testimonials
I've been dealing with Zenopa for two years and have found the entire team very helpful, swift and able to understand my needs.
Tushar, 2013

Otsuka receives positive EU opinion on new cancer drug

6 January 2011 00:00 in Pharmaceutical Company Product News


Otsuka has been granted a positive opinion from EU regulators for its subsidiary Taiho Pharmaceutical's new anti-cancer agent Teysuno.

The European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use has recommended the approval of the drug as a first-line therapy for advanced gastric cancer when used in combination with cisplatin.

It comes on the back of a recent phase III clinical trial, Flags, in which a Teysuno-containing treatment regimen was shown to offer a comparable efficacy and safety profile compared to the control drug.

Should the treatment receive EMA approval as expected, it will mark the first regulatory clearance achieved by Teysuno outside of Japan and Asia.

Toru Usami, president of Taiho Pharmaceutical, said: "Teysuno is the first of what we hope will be many promising anti-cancer agents to be developed globally and made commercially available by Taiho."

Last month, Otsuka and Bristol-Myers Squibb announced positive clinical data from a trial of Sprycel, their treatment for Philadelphia chromosome-positive chronic myelogenous leukaemia.ADNFCR-8000103-ID-800327919-ADNFCR

Other news stories from 06/01/2011

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency



                    
© Copyright 2014 Zenopa Ltd